Oxford vaccine administered to three at Vizag's KGH on day one of human trials  

Only healthy people and those above 18 years having no comorbidities, are being chosen for the trials. Selected volunteers will undergo clinical tests for Covid-19.

Published: 06th October 2020 09:48 AM  |   Last Updated: 06th October 2020 10:18 AM   |  A+A-

Dr PV Sudhakar, KGH Superintendent, administers Covishield vaccine to a volunteer on Monday.

Dr PV Sudhakar, KGH Superintendent, administers Covishield vaccine to a volunteer on Monday. (Photo | EPS)

Express News Service

VISAKHAPATNAM: Human trials for corona vaccine, Covishield, began at King George Hospital -Andhra Medical College here on Monday. Dr PV Sudhakar, KGH Superintendent and AMC principal, told TNIE that Covishield vaccine was administered to three volunteers on Day One. 

He said there will be gradual increase in number of  volunteers for the vaccine. Till now, 15 volunteers have enrolled their names for human trials. Registration of volunteers and human trials of vaccine go simultaneously. As many as 100 volunteers will be given  the vaccine at KGH. 

Only healthy people and those above 18 years having no comorbidities, are being chosen for the trials. Selected volunteers will undergo clinical tests for Covid-19.

Only corona negative persons will be administered the vaccine, Dr Sudhakar said. Testing of volunteers began on Saturday and, after getting the reports they began the exercise of administering vaccine to them on Monday, he said.

After administering the vaccine, blood samples will be collected from the volunteers so as to analyse the development of antibodies, he said. 

The vaccine will be administered on the first day, 29th day, 57th day and 90th day. They should come on the 180th day for the final visit. Blood samples will be sent immediately to Serum Institute of India (SII) at Pune for further tests.

About 1,600 people are undergoing human trials for the vaccine candidate across the country. The clinical trials results will be announced by the SII once the trials conclude, he said. 

An 18-member team, including a principal investigator, 10 co-investigators, seven supporting staff, is involved in administering the vaccine.

Dr Sudhakar said volunteers will be given vaccine injection after recording their body temperature and blood pressure. They will be under observation for half-an-hour and will be sent home. 

Also they will be given paracetamol tablet since they may get temperature.

The volunteers will be given Rs 500 for conveyance since it is purely a voluntary effort. He said on the first day, vaccine was administered to only three persons to ascertain logistic support at the facility.

The vaccine administration is a long procedure as they have to read out all conditions of vaccine to get the consent of the volunteer. 

He said volunteers will be given contact numbers of the hospitals to reach them if they develop any problem. If they don’t develop problems, they should visit on the stipulated dates for trials. 

Dr Sudhakar said the hospital PROs will be contacting the volunteers about their health status on a regular basis. 

The corona vaccine Covishield was developed jointly by Jenner Institute of the University of Oxford and British-Swedish pharma company, AstraZeneca. The Pune-based SII has partnered with AstraZeneca for manufacturing the Civud-19 vaccine in India.

More from Andhra Pradesh.

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.